Obesity management solutions offer a middle path for patients and providers. They help mitigate cost trends for payers and employers while maintaining access and providing equitable care to members and employees.
Ilant Health launched out of stealth Tuesday. The company serves employers and payers and helps identify patients in need of obesity treatment and matches them to the care best for them.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.
If we want to support people with obesity, the weight loss debate must stop conflating obesity prevention with obesity treatment. Instead, we should focus on the tools that best solve the needs of people where they are – just as we would for cancer or diabetes – by making the most effective treatments possible available.
Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
A new KFF analysis compared list prices for Ozempic, Wegovy, Rybelsus and Mounjaro. It found that the U.S. has much higher list prices for these drugs than other peer countries while also having the highest rate of obesity.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Novo Nordisk isn’t putting all of its weight loss drug hopes in the same basket. Its acquisition of Inversago Pharma for up to $1 billion will bring a biotech whose lead drug candidate has early clinical trial data showing significant weight loss.
Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
Hello Alpha launched Ahead with Alpha, a weight management program for employers. It offers access to primary care providers trained in obesity care, medication management through weight loss drugs like GLP-1s, nutrition counseling with a registered dietitian and progress tracking.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Treat and Reduce Obesity Act would expand Medicare coverage for obesity screenings, treatments and therapies like anti-obesity medications. The Health Equity Coalition for Chronic Disease came out in favor of the bill and asked for swift passage.
Alfie Health's $2.1 million seed funding was led by Y Combinator and Nina Capital. It included participation from Goodwater Capital, Phoenix Investment Club and several angel investors.
While the attention GLP-1s are receiving is exciting for medical professionals like me who've specialized in obesity treatment for decades, with little fanfare, the ‘miracle drug’ message is misleading and harmful.
Medicare is failing its beneficiaries by not treating obesity as a disease. Just like people with high blood pressure often need to take medications to avoid disease-related complications, people with obesity need access to all appropriate, evidence-based therapies to combat the disease.
Omada's new program provides coaching, peer support and educational materials to patients struggling with chronic obesity and taking GLP-1s. The company chose not to prescribe the weight loss drugs itself.